Clinical trial · Observational
Construction of a Predictive Model for the Efficacy of Chemoprevention Combined With Targeted Therapy in Pancreatic Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is a single-center, observational clinical trial designed to enroll a total of 70 pancreatic cancer patients. Tumor tissue sections from 60 patients will be retrospectively collected to establish a treatment response prediction model using spatial transcriptomics and other analyses. Fresh tumor tissue and blood samples from 10 patients will be prospectively collected to establish pancreatic cancer organoids and humanized immunocompetent mouse models for functional validation and exploration of the underlying molecular mechanisms.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Cancer Non-resectable | — | UNRESOLVED | — |
| Pancreatic Cancer Resectable | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Sample Collection | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Pancreatic ductal adenocarcinoma
- description
- Pancreatic cancer confirmed by pathology and imaging studies
- interventionNames
- Other: Sample Collection
Primary outcomes (2)
- measure
- Objective Best Tumor Response
- timeFrame
- 12 months
- description
- Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria.
- measure
- Overall Survival
- timeFrame
- 60 months
- description
- Overall survival is the duration from diagnosis to death. For patients who are alive, overall survival is censored at the last contact.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age 18 years or older * Pathologically and radiologically confirmed pancreatic cancer Exclusion Criteria: * Active malignancy other than pancreatic malignancy within the past 5 years or concurrently
References
Publications (0)
Data not yet available